AbbVie and REGENXBIO announce new partnership to develop and commercialise RGX-314

Sep 13, 2021

AbbVie and RegenXBio announced a partnership to develop and commercialise RGX-314 (proposed one-time gene therapy for the treatment of wet age-related macular degeneration, diabetic retinopathy and other chronic retinal diseases).

Print Page Mail Article